First-in-human study of TAS3681, an oral androgen receptor (AR) antagonist with AR and AR splice variant (AR-SV) downregulation activity, in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) refractory to abiraterone (ABI) and/or enzalutamide (ENZ) and chemotherapy (CT) Meeting Abstract
| Authors: | De Bono, J. S.; Cook, N.; Yu, E. Y.; Lara, P. N.; Wang, J. S.; Yamasaki, Y.; Yamamiya, I.; Gao, P.; Calleja, E. M.; Rathkopf, D. E. |
| Abstract Title: | First-in-human study of TAS3681, an oral androgen receptor (AR) antagonist with AR and AR splice variant (AR-SV) downregulation activity, in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) refractory to abiraterone (ABI) and/or enzalutamide (ENZ) and chemotherapy (CT) |
| Meeting Title: | 2021 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 39 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2021 Jun 4-8 |
| Meeting Location: | Virtual |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2021-05-20 |
| Language: | English |
| ACCESSION: | WOS:000708120603052 |
| DOI: | 10.1200/JCO.2021.39.15_suppl.5031 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 5031 -- Source: Wos |
